Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Neil Schrandt

Newark, DE Medical Doctor

NPI 1003842337 CMS profile 90800

620 Stanton Christiana Rd, Ste.302, Newark, DE 19713

Open in the dashboard

General payments

$8,942

482 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Neil Schrandt of Newark, DE is reported in the CMS Open Payments database as having received $8,942 across 482 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,114 53
2022 General $1,974 99
2021 General $1,948 114
2020 General $1,615 88
2019 General $2,291 128

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Neil Schrandt
  • Delaware median
  • Middle half of Delaware
  • National median

In program year 2025, general payments to Neil Schrandt were reported at $0. Among 3,573 Delaware profiles paid that year, the median was $159 and the middle half received between $48 and $505.

Show as a table
Year Neil Schrandt Delaware median Middle half National median
2019 $2,291 $159 $50–$594 $163
2020 $1,615 $100 $34–$344 $114
2021 $1,948 $119 $36–$464 $132
2022 $1,974 $136 $44–$486 $149
2023 $1,114 $149 $47–$522 $160
2024 $0 $163 $52–$524 $164
2025 $0 $159 $48–$505 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Biogen, Inc. $786 38 payments
  2. AbbVie, Inc. $717 46 payments
  3. Teva Pharmaceuticals USA, Inc. $559 35 payments
  4. Jazz Pharmaceuticals Inc. $522 20 payments
  5. Novartis Pharmaceuticals Corporation $480 27 payments
  6. Lilly USA, LLC $404 24 payments
  7. UCB, Inc. $391 16 payments
  8. Amgen Inc. $367 14 payments
  9. Genentech USA, Inc. $349 17 payments
  10. Alexion Pharmaceuticals, Inc. $238 14 payments
  11. Other $4,130 231 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $8,899 480 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $43 2 payments
Products named General payments · program years 2019–2023
  1. AIMOVIG $481 20 payments
  2. NURTEC ODT $445 34 payments
  3. VUMERITY $405 19 payments
  4. TYSABRI $303 14 payments
  5. EMGALITY $292 18 payments
  6. OCREVUS $291 15 payments
  7. DUOPA $254 15 payments
  8. AJOVY $241 13 payments
  9. ZEPOSIA $234 14 payments
  10. SUNOSI $210 10 payments
  11. Other $6,443 361 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

482 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record